South Korean aesthetic device maker Classys attended the Jefferies Healthcare Conference in the United States, marking the first time a medical aesthetics device company was invited to the event, traditionally dominated by large pharma and biotech firms. The company highlighted its growing North American footprint and multi-device strategy, signaling opportunities for distributors and clinics eyeing K-beauty device partnerships.
Conference milestone
Classys participated in the Jefferies Healthcare Conference, Europe's largest healthcare gathering with over 500 companies and 3,000 investors, on November 5. The invitation signals growing recognition of medical aesthetics devices as a distinct investment theme within global healthcare.
North America performance
Kim Rae-hee, head of marketing at Classys, presented the company's differentiated competitiveness. Last year, Classys surpassed 300 cumulative installations of its Monopolar Radiofrequency (MRF) devices in North America. In Q1 alone, after launching its Microneedle Radiofrequency (MNRF) device, it sold over 100 units combined. The company expects its North American revenue share to reach 15% by 2030, supported by an upcoming High-Intensity Focused Ultrasound (HIFU) device approval next year.
Clinical and market traction
Classys reported that its combination treatment protocols have gained word-of-mouth among local practitioners and consumers, boosting repeat visits. Forbes has cited the treatment as one of the most popular aesthetic procedures. The company continues to publish clinical papers supporting its key products, Everes and Quadsea.
Global expansion milestones
Quadsea has begun full-scale sales in the US and Thailand, targeting 1,000 global unit sales this year. Ultraformer and Volumer are growing rapidly in key European markets. In Japan, Classys is finalizing orders from large clinic chains, while in China, Volumer's regulatory approval is expected within the year. Combined global sales of these two products are projected to exceed 5,000 units annually. Market analysts see the company's 2024 revenue guidance of KRW 490 billion as increasingly achievable.
What buyers should watch
Distributors and clinic buyers should monitor Classys' expanding device portfolio—MRF, MNRF, and upcoming HIFU—which offers cross-selling opportunities for consumables. The company's recurring consumable revenue model and country-specific product strategies were well received by investors. With K-beauty gaining traction as a global healthcare investment theme, Classys' multi-device approach and expanding regulatory approvals in the US, Europe, Japan, and China present clear sourcing and partnership opportunities.
Source: Read the original report | Published: June 05, 2026